99888 Federal Register / Vol. 89, No. 238 / Wednesday, December 11, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Anti–KK–LC–1 T Cell 

Receptors for the Treatment of Cancer 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an Exclusive 

Patent License to practice the inventions 

embodied in the Patents and Patent 

Applications listed in the 

Supplementary Information section of 

this notice to StraightLine Bio, Inc. 

located in Princeton, New Jersey. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before December 26, 2024 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Suna Gulay French, Ph.D., 

Technology Transfer Manager, NCI 

Technology Transfer Center at 

Telephone; (240)–276–5530, Email: 

suna.gulay@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 62/327,529, filed April 

26, 2016 and entitled ‘‘Anti–KK–LC–1 T 

Cell Receptors’’ [HHS Reference No. E– 

153–2016–0–US–01]; 

2. PCT Patent Application No. PCT/ 

US2017/027865, filed April 17, 2017 

and entitled ‘‘Anti–KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–PCT–02]; 

3. Australian Patent No. 2017258745, 

issued July 14, 2022 and entitled ‘‘Anti– 

KK–LC–1 T Cell Receptors’’ [HHS 

Reference No. E–153–2016–0–AU–03]; 

4. Canadian Patent Application No. 

3021898, filed April 17, 2017 and 

entitled ‘‘Anti–KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–CA–04]; 

5. European Patent No. 3448882, 

issued November 24, 2021 and entitled 

‘‘Anti–KK–LC–1 T Cell Receptors’’ 

[HHS Reference No. E–153–2016–0–EP– 

05]; 

a. Validated in the following 

jurisdictions: CH, DE, BE, DK, ES, FI, 

FR, GB, IE, IT, NL, NO and SE. 

6. U.S. Patent No. 11,352,410, issued 

June 7, 2022 and entitled ‘‘Anti–KK– 

LC–1 T Cell Receptors’’ [HHS Reference 

No. E–153–2016–0–US–06]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the 

following: 

Development, manufacture and 

commercialization of autologous T cell 

therapy products that are genetically 

engineered via retroviral-mediated gene 

transfer or CRISPR-based gene transfer 

or transposon-mediated gene transfer to 

express a T cell receptor (TCR) targeting 

human Kita-Kyushu Lung Cancer 

Antigen 1 (KK–LC–1) restricted to HLA– 

A*01, as claimed in the Licensed Patent 

Rights, for the treatment of KK–LC–1 

positive cancers and premalignant 

conditions in humans. 

For the avoidance of doubt, 

specifically excluded from the Field of 

Use are: 

1. Development, manufacture, and 

commercialization of Natural Killer cell 

therapy products engineered via viral 

vectors (including lentivirus or 

retrovirus) to express the TCR(s) 

claimed in the Licensed Patent Rights; 

and 

2. Development, manufacture and 

commercialization of a combination 

therapy for the treatment of KK–LC–1 

positive human cancers that do not have 

the HLA–A*01 genotype, wherein the 

treatment comprises as a step: 

Modification of the patient’s tumor to 

express the HLA–A*01 restriction 

element. 

This technology discloses isolated T 

cell receptors (TCR) reactive to the KK– 

LC–1) within the context of human 

leukocyte antigen (HLA) A*01:01. KK– 

LC–1 is expressed by various epithelial 

cancers including carcinomas of the 

bladder, cervix, stomach, breast, lung, 

and pancreas. Due to its minimal 

expression in normal tissues, this 

antigen may be targeted on KK–LC–1— 

expressing tumors with minimal normal 

tissue toxicity. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Date: December 6, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–29076 Filed 12–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Resource Related 

Research Projects (R24 Clinical Trial Not 

Allowed). 

Date: January 30, 2025. 

Time: 10:30 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G56, 

Rockville, MD 20892 (Video Assisted). 

Contact Person: Maryam Rohani, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G56, Rockville, MD 

20892, (301) 761–6656, maryam.rohani@

nih.gov. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 238 / Wednesday, December 11, 2024 / Notices 99889 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: December 4, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–29022 Filed 12–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket Number USCG–2021–0183] 

Final Programmatic Environmental 

Impact Statement for the Expansion 

and Modernization of Base Seattle 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of Availability; extension 

of waiting period for the Final 

Programmatic Environmental Impact 

Statement Expansion and 

Modernization of Base Seattle. 

SUMMARY: The Coast Guard is extending 

the waiting period for the Final 

Programmatic Environmental Impact 

Statement (PEIS) for the proposed 

Expansion and Modernization of Base 

Seattle. We published a Notice of 

Availability of the Final PEIS on 

November 15, 2024. That notice marked 

the start of a 30-day waiting period. We 

are extending the wait period. January 

10, 2025, is the earliest date that the 

Coast Guard would issue a final 

decision. 

DATES: The Coast Guard will not issue 

a final decision on the proposed action 

until at least January 10, 2025. 

ADDRESSES: The complete text of the 

Final PEIS is available in the docket, 

which can be found by searching the 

docket number USCG–2021–0183 using 

the Federal eRulemaking Portal at 

https://www.regulations.gov or at 

https://www.dcms.uscg.mil/NEPA. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information 

should be sent to U.S. Coast Guard, 

Shore Infrastructure Logistics Center, 

Environmental Management Division, 

ATTN: Dean Amundson, 1301 Clay 

Street, Suite 700N, Oakland, CA 94612– 

5203; phone 510–637–5541; email 

BaseSeattlePEIS@uscg.mil. 

SUPPLEMENTARY INFORMATION: The Final 

PEIS was prepared in accordance with 

the requirements of the National 

Environmental Policy Act (NEPA), the 

Council on Environmental Quality 

regulations implementing NEPA (40 

CFR 1500–1508), DHS procedures for 

implementing NEPA (DHS Instruction 

Manual 023–01–001–01 (series)), Coast 

Guard Environmental Planning Policy 

(Commandant Instruction 

[COMDTINST] 5090.1), and other 

applicable DHS and Coast Guard 

policies and guidance. A Notice of 

Intent (NOI) to prepare the PEIS was 

published in the Federal Register on 

May 7, 2021 (86 FR 24637). On October 

11, 2022, the Coast Guard published a 

Notice of Availability (NOA) and a 

request for comments on the Draft PEIS 

(87 FR 61344). In response to a 

comment in the Docket the Coast Guard 

extended the Public Comment Period 

until December 16, 2022, which was 

announced in the Federal Register (87 

FR 73011) and in local newspapers on 

November 28, 2022. 

The NOA for the Final PEIS was 

published on November 15, 2024, and 

the original wait period would have 

concluded on December 16, 2024. The 

Coast Guard will extend the wait period 

for the Final PEIS to allow for additional 

time for public review due to the 

complexity of the proposed action and 

the presence of multiple federal 

holidays during the review period. The 

Coast Guard will not issue a Record of 

Decision until after January 10, 2025. 

For more detailed information, please 

see the original notice titled ‘‘Final 

Programmatic Environmental Impact 

Statement for the Expansion and 

Modernization of Base Seattle’’ 

published on November 15, 2024 (89 FR 

90302). A copy of that notice is also 

available in the docket. 

Following the wait period concluding 

on January 10, 2025, the Coast Guard 

will announce its Record of Decision, 

which will be published in the Federal 

Register. 

Dated: December 5, 2024. 

A. Grable, 

Rear Admiral, U.S. Coast Guard, Assistant 

Commandant for Engineering and Logistics. 

[FR Doc. 2024–29048 Filed 12–10–24; 8:45 am] 

BILLING CODE 9110–04–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA 2024–0034; OMB No. 

1660–0068] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; Federal Hotel and 

Motel Fire Safety Declaration Form 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: 60-Day notice of Extension 

extension and request for comments. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA), as part of 

its continuing effort to reduce 

paperwork and respondent burden, 

invites the general public to take this 

opportunity to comment on an 

extension, without change, of a 

currently approved information 

collection. In accordance with the 

Paperwork Reduction Act of 1995, this 

notice seeks comments concerning a list 

of hotels, motels, and similar places of 

public accommodations meeting 

minimum fire-safety requirements. The 

information collected is voluntary and if 

approved for listing, the lodging 

establishment may be used by Federal 

employees on government related travel 

and for Federal agency conferences. As 

the list is open to use by the public, 

non-government travelers may use the 

list to identify lodging meeting 

minimum life-safety criteria from fire. 

DATES: Comments must be submitted on 

or before February 10, 2025. 

ADDRESSES: To avoid duplicate 

submissions to the docket, please 

submit comments at 

www.regulations.gov under Docket ID 

FEMA–2024–0034. Follow the 

instructions for submitting comments. 

All submissions received must 

include the agency name and Docket ID. 

Regardless of the method used for 

submitting comments or material, all 

submissions will be posted, without 

change, to the Federal eRulemaking 

Portal at http://www.regulations.gov, 

and will include any personal 

information you provide. Therefore, 

submitting this information makes it 

public. You may wish to read the 

Privacy and Security Notice that is 

available via a link on the homepage of 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Teressa Kaas, Fire Program Specialist, 

FEMA/U.S. Fire Administration, 301– 

447–1263, and teressa.kaas@ 


lotter on DSK11XQN23PROD with NOTICES1